ForteBio Launches New Assay Capabilities for High-Sensitivity Protein Quantitation...

ForteBio Launches New Assay Capabilities for High-Sensitivity Protein
Quantitation and Fragment Screening on Its Octet(R) Platform

MENLO PARK, Calif., May 27 /PRNewswire/ -- ForteBio(R), Inc., a leading
supplier of label-free technology that accelerates the development of
biotherapeutic and pharmaceutical products, today announced that it has
launched two new assay modules - for high-sensitivity protein quantitation and
fragment screening, respectively - for use on the company's Octet(R)
instrumentation platform. The new modules are available via software upgrades
and will enable, for the first time, life science researchers who require
these capabilities to access the high-throughput, ease-of-use and
cost-effectiveness of ForteBio's leading label-free technology.

The new high-sensitivity assay module can detect low nanogram per mL levels of
analytes in quantitation mode. "For protein quantitation, life science
researchers have traditionally run fluorescence and luminescence ELISA methods
to achieve greater sensitivity in their assays. Now, using ForteBio's new
modules, they can obtain highly precise results within an hour, enabling
follow-up research to be conducted the same day," said Christopher Silva,
ForteBio's vice president of marketing. "Additionally, labs that have
transitioned from ELISA techniques to the Octet platform have improved their
productivity by 50 to 70 percent, with no additional cost per well."
ForteBio's off-the-shelf biosensors can be regenerated online, enabling the
cost per well to begin at approximately 10 cents, while custom quantitation
assays can be run by biotinylating the protein of interest using streptavidin
biosensors.

The new fragment screening assay methodology extends the company's small
molecule analysis capabilities - available on ForteBio's Octet RED system - by
enabling kinetic characterization and screening of fragment libraries that
include compounds in the 150 to 300 dalton range. "Fragment-based lead
generation is becoming an increasingly important component of drug discovery,"
said Mr. Silva. "Currently, fragment screening assays are typically run on
lower-throughput, microfluidic-based SPR systems, which can become a
bottleneck in the drug discovery process. The Octet platform's sensitivity and
ability to assay precipitating compounds using a 'dip and read' format, its
greater dynamic range and our new analysis software capabilities, enable rapid
screening of fragment libraries in a microplate format."

ForteBio's Octet biosensors are configured in a standard microplate format.
Its biosensors simplify quantitation and kinetic characterization by
eliminating throughput limitations of traditional SPR-based systems. Octet
biosensors are coated with a proprietary biocompatible matrix that is uniform,
non-denaturing and has minimal non-specific binding.

About ForteBio, Inc.
ForteBio is a life science company that provides analytical systems to
accelerate biotherapeutic drug discovery and development. These systems enable
real-time, label-free analysis of biomolecular interactions, providing
information on affinity, kinetics and concentration. ForteBio's analytical
capabilities enable significantly easier, faster and better characterization
of drug candidates, thus providing greater value in drug development
applications where existing methods have limitations in throughput,
performance and cost. The company is headquartered in Menlo Park, California,
with wholly owned subsidiaries in London and Shanghai. For more information,
visit www.fortebio.com.

SOURCE ForteBio, Inc.

Gemma Milan of ForteBio, Inc., +1-650-289-6800, gmilan@fortebio.com